An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its first quarter financial and operational results on May 2, 2024. The management team will host a conference call/webcast to review the results and provide a business update.
Positive
None.
Negative
None.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2024 on Thursday, May 2, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.
Interested participants can dial 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada). The audio webcast can also be accessed here. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.
Aurinia Pharmaceuticals will release its first quarter financial and operational results on May 2, 2024.
The ticker symbol for Aurinia Pharmaceuticals is AUPH.
Interested participants can access the conference call/webcast by dialing 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada) or through the audio webcast on Aurinia's website.
Yes, a replay of the webcast will be available on Aurinia's website.
